Literature DB >> 22282203

[Fund for Protection against Catastrophic Expenses].

Belkis Aracena-Genao1, María Cecilia González-Robledo, Luz María González-Robledo, Lina Sofía Palacio-Mejía, Gustavo Nigenda-López.   

Abstract

OBJECTIVE: To document the status of operational and managerial processes of the Fund for Protection against Catastrophic Expenses (FPGC), as well as to describe its evolution, and to explore the relationship between covered diseases and the Mexican health profile.
MATERIAL AND METHODS: This is a joint management study, which included a qualitative and a quantitative phase. We conducted semi-structured interviews with key informants. We also analyzed the records of CNPSS, the hospital discharge and mortality data bases.
RESULTS: Fifty two percent of the states take twice as long to report and validate the cases. From 2004-2009 the FPGC increased its coverage from 6 to 49 interventions, that means a spending increase of 2 306.4% in nominal terms and 1 659.3% in real terms. The HIV/AIDS was the intervention prioritized with 39.3% and Mexico City had the highest proportion of expenditure (25.1%). A few diseases included in the health profile are covered by the FPGC.
CONCLUSIONS: The review of the inclusion criteria of diseases is urgent, so as to cover diseases of epidemiological importance.

Entities:  

Mesh:

Year:  2011        PMID: 22282203     DOI: 10.1590/s0036-36342011001000004

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  2 in total

1.  CD4 Counts at Entry to HIV Care in Mexico for Patients under the "Universal Antiretroviral Treatment Program for the Uninsured Population," 2007-2014.

Authors:  Alfonso C Hernández-Romieu; Carlos del Rio; Juan Eugenio Hernández-Ávila; Hugo Lopez-Gatell; José Antonio Izazola-Licea; Patricia Uribe Zúñiga; Mauricio Hernández-Ávila
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

2.  Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios.

Authors:  María Cecilia González-Robledo; Rebeca Wong; Héctor Arreola Ornelas; Felicia Marie Knaul
Journal:  Ecancermedicalscience       Date:  2015-10-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.